Emergent BioSolutions | EBS - Current Liabilities


Emergent BioSolutions reported $651.3M in Current Liabilities for its fiscal quarter ending in December of 2023.





Current Liabilities Change Date
Acadia Pharmaceuticals USD 305.52M 28.41M Mar/2026
Akebia Therapeutics USD 173.88M 10.95M Mar/2026
ALKERMES USD 599.5M 56.06M Mar/2026
Alnylam Pharmaceuticals USD 1.35B 116.87M Mar/2026
Amarin USD 179.64M 14.82M Mar/2026
ANI Pharmaceuticals USD 239.51M 38.6M Mar/2026
BioMarin Pharmaceutical USD 793.15M 34.12M Mar/2026
Coherus Biosciences USD 140.39M 231.91M Dec/2025
Emergent BioSolutions USD 651.3M 12.7M Dec/2023
Exelixis USD 370.98M 34.67M Mar/2026
Glaxosmithkline GBP 28.82B 144.79M Dec/2025
Heron Therapeutics USD 90.52M 5.58M Mar/2026
Ionis Pharmaceuticals USD 717M 66M Mar/2026
Ironwood Pharmaceuticals USD 236.31M 5.91M Mar/2026
Lexicon Pharmaceuticals USD 9.9M 10.97M Mar/2026
Lonza CHF 3.57B 421M Dec/2025
Merck USD 26.94B 1.38B Mar/2026
Moderna USD 2.4B 408M Mar/2026
Myriad Genetics USD 130.2M 3.6M Mar/2026
Nektar Therapeutics USD 53.54M 12.8M Dec/2025
Neurocrine Biosciences USD 831.7M 88.3M Mar/2026
Pacira USD 108.79M 11.8M Mar/2026
Pfizer USD 34.35B 2.64B Mar/2026
PTC Therapeutics USD 923.6M 44.82M Mar/2026
Sanofi EUR 30.01B 1.66B Mar/2026
Sarepta Therapeutics USD 499.16M 596.13M Mar/2026
United Therapeutics USD 599.1M 38.5M Mar/2026
Vanda Pharmaceuticals USD 145.16M 27.29M Dec/2025
Xoma USD 28.3M 6.81M Sep/2025